Corline Biomedical AB (STO:CLBIO)

Market Cap	422.05M +33.1%
Revenue (ttm)	11.85M +37.2%
Net Income	-12.32M
EPS	-0.48
Shares Out	26.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,101
Open	16.10
Previous Close	16.15
Day's Range	15.60 - 16.15
52-Week Range	14.00 - 27.20
Beta	0.30
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 2, 2026

About Corline Biomedical AB

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company’s products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. It offers CHS stent, a metallic tube-shaped device for the treatment of acute or threatened vessel closure during coronary angiop...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1991
• Employees: 13
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CLBIO

Financial Performance

In 2025, Corline Biomedical AB's revenue was 7.65 million, a decrease of -21.73% compared to the previous year's 9.78 million. Losses were -14.71 million, -36.56% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 2, 2026

Data Sources Report a data error